Analysis of Patients With Incidental Perihilar Cholangiocarcinoma: An Old and a Persistent Burden for Liver Transplantation.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 04 01 2020
revised: 31 01 2020
accepted: 09 02 2020
pubmed: 21 4 2020
medline: 29 12 2020
entrez: 21 4 2020
Statut: ppublish

Résumé

Selected patients with unresectable perihilar cholangiocarcinoma (p-CCA) are now considered as candidates for liver transplant, provided they fulfill a strict perioperative treatment and staging protocol. The aim of this study was to examine the outcomes of patients after liver transplant with incidental p-CCA found in the liver explants. A cohort of 10 patients with incidental p-CCA after liver transplant in the period between 1994 and 2019 was included in this retrospective analysis. All patients with this diagnosis were scheduled for transplant because of primary sclerosing cholangitis. The primary and secondary endpoints comprised patient's death and tumor recurrence, respectively, assessed over a 5-year postoperative period. Patient median age was 35 years (range, 32-42 years). Median size of the tumor was 3.0 cm (range, 2.5-4.0 cm). Five patients (50%) had metastases to local lymph nodes. Overall survival was 100%, 37.5%, and 18.8% after the first, third, and fifth postoperative year, respectively, with median survival of 21 months. Patient age (P = .827), R1 resection status (P = .144), tumor diameter (P = .432), and presence of lymph node metastases (P = .663) were not significantly associated with overall survival. Recurrence-free survival was 60.0% after the first postoperative year and 22.5% after the third and fifth postoperative years, with median recurrence-free survival of 13.6 months. No significant predictors of tumor recurrence were found. Incidental p-CCA in patients with primary sclerosing cholangitis undergoing liver transplant is associated with universally very high risk of postoperative tumor recurrence and short expected survival.

Sections du résumé

BACKGROUND BACKGROUND
Selected patients with unresectable perihilar cholangiocarcinoma (p-CCA) are now considered as candidates for liver transplant, provided they fulfill a strict perioperative treatment and staging protocol. The aim of this study was to examine the outcomes of patients after liver transplant with incidental p-CCA found in the liver explants.
METHODS METHODS
A cohort of 10 patients with incidental p-CCA after liver transplant in the period between 1994 and 2019 was included in this retrospective analysis. All patients with this diagnosis were scheduled for transplant because of primary sclerosing cholangitis. The primary and secondary endpoints comprised patient's death and tumor recurrence, respectively, assessed over a 5-year postoperative period.
RESULTS RESULTS
Patient median age was 35 years (range, 32-42 years). Median size of the tumor was 3.0 cm (range, 2.5-4.0 cm). Five patients (50%) had metastases to local lymph nodes. Overall survival was 100%, 37.5%, and 18.8% after the first, third, and fifth postoperative year, respectively, with median survival of 21 months. Patient age (P = .827), R1 resection status (P = .144), tumor diameter (P = .432), and presence of lymph node metastases (P = .663) were not significantly associated with overall survival. Recurrence-free survival was 60.0% after the first postoperative year and 22.5% after the third and fifth postoperative years, with median recurrence-free survival of 13.6 months. No significant predictors of tumor recurrence were found.
CONCLUSIONS CONCLUSIONS
Incidental p-CCA in patients with primary sclerosing cholangitis undergoing liver transplant is associated with universally very high risk of postoperative tumor recurrence and short expected survival.

Identifiants

pubmed: 32307142
pii: S0041-1345(20)30017-8
doi: 10.1016/j.transproceed.2020.02.094
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2507-2511

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Maciej Krasnodębski (M)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland. Electronic address: mwkrasn@gmail.com.

Michał Grąt (M)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Michał Wierzchowski (M)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Michalina Szczęśniak (M)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Marcin Morawski (M)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Krzysztof Zając (K)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Waldemar Patkowski (W)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Krzysztof Zieniewicz (K)

Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH